- Home
- GLUE vs STEL Comparison
GLUE vs STEL Comparison
Compare GLUE & STEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | STEL |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | 1053 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GLUE | STEL |
|---|---|---|
| Price | $18.74 | $37.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $32.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 644.3K | 214.1K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $123,672,000.00 | $6,282,000.00 |
| Revenue This Year | N/A | $10.14 |
| Revenue Next Year | $2.45 | $4.65 |
| P/E Ratio | $72.42 | ★ $69.72 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $3.90 | $26.08 |
| 52 Week High | $25.77 | $40.21 |
Technical Indicators
Market Signals| Indicator | GLUE | STEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 53.28 |
| Support Level | $18.51 | $36.95 |
| Resistance Level | $21.04 | $38.10 |
| Average True Range (ATR) | 1.02 | 0.55 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 33.59 | 64.15 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About STEL Stellar Bancorp Inc.
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc. and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.